Geneva, Switzerland, 4 June 2008 - Addex Pharmaceuticals (SWX: ADXN) announced that it has started Study 105, a Phase I clinical trial evaluating the interaction of a new formulation of ADX10059 with proton pump inhibitors and food. A formulation of ADX10059 was selected at the end of May, upon completion of part one of Study 104, a separate ongoing Phase I trial.
